Beneficial/probiotic strains protect the host from pathogens by competitive displacement and production of antibacterial substances, i.e., bacteriocins. The antiparasitic potential of bacteriocins/enterocins and their producing strains in experimental murine trichinellosis were tested as a new therapeutic strategy. Enterocin M and Durancin-like and their
[...] Read more.
Beneficial/probiotic strains protect the host from pathogens by competitive displacement and production of antibacterial substances, i.e., bacteriocins. The antiparasitic potential of bacteriocins/enterocins and their producing strains in experimental murine trichinellosis were tested as a new therapeutic strategy. Enterocin M and Durancin-like and their producers
Enterococcus faecium CCM8558 and
Enterococcus durans ED26E/7 were administered daily to mice that were challenged with
Trichinella spiralis. Our study confirmed the antiparasitic effect of enterocins/enterococci, which reduced the number of adults in the intestine (Enterocin M—43.8%,
E. faecium CCM8558—54.5%, Durancin-like—16.4%,
E. durans ED26E/7—35.7%), suppressed the
Trichinella reproductive capacity ex vivo (Enterocin M—61%,
E. faecium CCM8558—74%, Durancin-like—38%,
E. durans ED26E/7—66%), and reduced the number of muscle larvae (Enterocin M—39.6%,
E. faecium CCM8558—55.7%, Durancin-like—15%,
E. durans ED26E/7—36.3%). The direct effect of enterocins on
Trichinella fecundity was documented by an in vitro test in which Durancin-like showed a comparable reducing effect to Enterocin M (40–60%) in contrast to the ex vivo test. The reducing activity of
T.spiralis infection induced by Enterocin M was comparable to its strain
E. faecium CCM8558; Durancin-like showed lower antiparasitic activity than its producer
E. durans ED26E/7.
Full article